Jinling Pharmaceutical Company Limited

XSEC:000919 Stock Report

Market Cap: CN¥4.2b

Jinling Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Jinling Pharmaceutical has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.9% per year. Jinling Pharmaceutical's return on equity is 1.6%, and it has net margins of 2.5%.

Key information

0.5%

Earnings growth rate

-0.02%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate2.9%
Return on equity1.6%
Net Margin2.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jinling Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:000919 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,90273425101
30 Jun 242,8557442489
31 Mar 242,82410042986
31 Dec 232,78610042479
30 Sep 232,72111041271
30 Jun 232,76012440182
31 Mar 232,68611038679
01 Jan 232,67110538574
30 Sep 222,75211637963
30 Jun 222,73910438354
31 Mar 222,80012538560
01 Jan 222,80912138357
30 Sep 212,7968539354
30 Jun 212,78311738047
31 Mar 212,69212835141
31 Dec 202,5046532844
30 Sep 202,413-1330645
30 Jun 202,389-5830347
31 Mar 202,435-9332445
31 Dec 192,53514534944
30 Sep 192,53235934334
30 Jun 192,62338037530
31 Mar 192,72140539229
01 Jan 192,89924242734
30 Sep 183,03211352149
30 Jun 183,04612648960
31 Mar 183,15214149653
31 Dec 173,19213747939
30 Sep 173,39117041018
30 Jun 173,4811714310
31 Mar 173,5401754390
31 Dec 163,5791804440
30 Sep 163,5262004590
30 Jun 163,4622024430
31 Mar 163,3791994590
31 Dec 153,2212084460
30 Sep 153,0611974300
30 Jun 152,9582044370
31 Mar 152,8492144260
31 Dec 142,7721974070
30 Sep 142,7811964290
30 Jun 142,7081834100
31 Mar 142,6391663820
31 Dec 132,6061563780

Quality Earnings: 000919 has a large one-off gain of CN¥31.5M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 000919's current net profit margins (2.5%) are lower than last year (4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 000919's earnings have grown by 0.5% per year over the past 5 years.

Accelerating Growth: 000919's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 000919 had negative earnings growth (-33.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 000919's Return on Equity (1.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 20:13
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jinling Pharmaceutical Company Limited is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jessica LiBofA Global Research
Han Wei YuChina Stock Investment Research Co. Ltd. (GZ500..com)
Weina JiangEverbright Securities Co. Ltd.